Skip to main content
. 2023 Sep 1;4(9):659–667. doi: 10.1302/2633-1462.49.BJO-2023-0065.R1

Table III.

Management of periprosthetic fractures.

Variable Total UCS p-value
AG AL B1 B2 B3 C D E
Patients, n (%) 1,104 94 (8.5) 19 (1.7) 337 (30.5) 368 (33.3) 105 (9.5) 136 (12.3) 44 (4) 1 (0.1)
Treatment method, n (%) < 0.001*
Conservative 131 (11.9) 69 (73.4) 13 (68.4) 29 (8.6) 11 (3) 6 (5.7) 2 (1.5) 1 (2.3) 0
ORIF 585 (53) 17 (18.1) 5 (26.3) 268 (79.5) 109 (29.6) 28 (26.7) 123 (90.4) 35 (79.6) 0
Revision arthroplasty 189 (17.1) 3 (3.2) 1 (5.3) 18 (5.3) 113 (30.7) 42 (40) 6 (4.4) 6 (13.6) 0
ORIF + revision arthroplasty 199 (18) 5 (5.3) 0 22 (6.5) 135 (36.7) 29 (27.6) 5 (3.7) 2 (4.6) 1 (100)
Revision with endoprosthesis 29 (2.6) 1 (1.1) 0 3 (0.9) 8 (2.2) 12 (11.4) 1 (0.7) 4 (9.1) 0
Time from presentation to surgery, days
Mean (SD) 4.5 (6.6) 7.7 (17.5) 4.7 (4.9) 4 (3.9) 5.2 (7.6) 4.5 (4) 3 (3.5) 4.7 (11.5) 3 0.001
Median (IQR) 3 (2 to 5) 4 (2 to 6) 2.5 (1 to 8) 3 (2 to 5) 4 (2 to 6) 3 (2 to 6) 2 (1 to 3) 2 (1 to 4) 3
Speciality of operating surgeon, n (%) < 0.001*
Arthroplasty surgeon 819 (84.2) 23 (92) 6 (100) 252 (81.8) 330 (92.4) 87 (87.9) 88 (65.7) 33 (76.7) 0
Trauma/general/other 146 (15) 2 (8) 0 52 (16.9) 26 (7.3) 12 (12.1) 45 (33.6) 8 (18.6) 1 (100)
Unknown 8 (0.8) 0 0 4 (1.3) 1 (0.3) 0 1 (0.7) 2 (4.7) 0
*

Chi-squared test.

Kruskal-Wallis test.

IQR, interquartile range; ORIF, open reduction and internal fixation; SD, standard deviation.